Caplin Point Lab's subsidiary receives USFDA nod for Neostigmine Methylsulfate Injection

According to IQVIATM (IMS Health), Neostigmine Methylsulfate Injection had US sales data of approximately $20 million for the 12-month period ending Dec 2020.

Apr 22, 2021 11:04 IST India Infoline News Service

Caplin Point
Caplin Steriles a Subsidiary Company of Caplin Point Laboratories Limited, has informed regarding the USFDA approval for Neostigmine Methylsulfate Injection.

The Company has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Neostigmine Methylsulfate Injection USP, 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL), Multiple-Dose vial presentations, a generic therapeutic equivalent version of (RLD), BLOXIVERZ Injection, of Exela Pharma Sciences, LLC, USA.

Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

According to IQVIATM (IMS Health), Neostigmine Methylsulfate Injection had US sales data of approximately $20 million for the 12-month period ending Dec 2020.

Caplin Point Laboratories was trading at Rs519 apiece up by Rs11.8 or 2.33% from its previous closing of Rs507.20 apiece on the BSE, at around 11:42 AM.

Related Story

Open Free Demat Account (Rs699)